低氧诱导的PRMT1乳化促使瘤转移中的维门丁氨酸不对称二甲基化
Jia Zhou1, Shuying Qiu1, Xia Yang2
1Department of Medical Oncology, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|August 30, 2025
概括
低氧会触发蛋白质阿尔金因甲基转移酶1 (PRMT1) 乳化,增加其活性以修改维门丁并驱动癌症转移. 针对这种低氧-PRMT1-维门丁轴提供了一种新的抗转移策略.
科学领域:
- 癌症学
- 分子生物学
- 生物化学
背景情况:
- 转移是癌症死亡的主要原因,有效治疗方法有限.
- 缺氧诱导的上皮介质转变 (EMT) 驱动癌细胞的扩散.
- 在EMT中控制细胞骨变化的翻译后修饰尚未完全理解.
研究的目的:
- 阐明将低氧与细胞骨架重塑和癌症转移联系在一起的转化后机制.
- 确定抑制癌症转移的新疗法目标.
主要方法:
- 使用生物化学测定和细胞培养模型研究低氧诱导蛋白质修饰.
- 使用基因沉默 (shPRMT1) 和位点定向突变 (vimentin R64K,PRMT1 K134R/K145R) 来评估功能影响.
- 在不同氧气条件下分析PRMT1,维门丁和HDAC8的蛋白质含量.
- 与三阴性乳腺癌 (TNBC) 的临床数据相关的维门丁R64非对称二甲基化水平.
- 在临床前转移模型中评估PRMT1抑制剂 (MS023) 的疗效.
主要成果:
- 在K134/K145中诱导PRMT1乳化,增强其活性.
- 乳化PRMT1在R64催化了维门丁非对称二甲基化 (aDMA),促进了线程组装和细胞骨重塑.
- 抑制PRMT1或维门丁R64突变导致缺氧驱动的迁移和转移.
- 低氧会降低HDAC8 (PRMT1脱乳酶) 的水平,从而增加PRMT1的乳化.
- PRMT1 K134R/K145R突变未能结合维门丁或救援丝形成.
- 维门丁R64aDMA水平与晚期TNBC和低生存率相关.
- 在异种移植中,PRMT1抑制剂MS023降低了转移,毒性最小.
结论:
- 一个新的缺氧-PRMT1-维门丁信号轴调节癌症转移.
- 维门丁R64aDMA是转移的一个关键媒介.
- 向PRMT1活动是对抗癌症转移的有希望的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K


